Neurologic Wilson's disease

Annals of the New York Academy of Sciences

Volumn 1184, Issue , 2010, Pages 173-187

  Lorincz, Matthew T ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Ceruloplasmin; Copper; Dysarthria; Dystonia; Movement disorders; Parkinsonism; Tremor

Indexed keywords

BACLOFEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERULOPLASMIN; COPPER; CORTICOSTEROID; DIAZEPAM; DIMERCAPROL; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PENICILLAMINE; PRIMIDONE; TETRATHIOMOLYBDIC ACID; TRIENTINE; TRIHEXYPHENIDYL; ZINC ACETATE; ADENOSINE TRIPHOSPHATASE; CATION TRANSPORT PROTEIN; WILSON DISEASE PROTEIN;

ANEMIA; ATAXIA; AUTOSOMAL INHERITANCE; BRAIN DISEASE; CERULOPLASMIN BLOOD LEVEL; CHOREOATHETOSIS; CLINICAL TRIAL; COGNITIVE DEFECT; DEATH; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSARTHRIA; DYSTONIA; ESSENTIAL TREMOR; EYE DISEASE; GAIT DISORDER; HUMAN; HYPERREFLEXIA; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; LIVER FAILURE; MENTAL DISEASE; MOLECULAR GENETICS; NEUROLOGICAL COMPLICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PATHOGENESIS; REVIEW; SCREENING; SEIZURE; SIDE EFFECT; SLIT LAMP; SPEECH THERAPY; STEREOTYPY; STOMACH DISCOMFORT; SYSTEMIC LUPUS ERYTHEMATOSUS; THERAPY DELAY; THROMBOCYTOPENIA; TIC; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT; WILSON DISEASE; ADOLESCENT; ADULT; CHILD; GENETICS; METABOLISM; MUTATION; ONSET AGE; PATHOLOGY;

ADENOSINE TRIPHOSPHATASES; ADOLESCENT; ADULT; AGE OF ONSET; ATAXIA; CATION TRANSPORT PROTEINS; CHILD; COGNITION DISORDERS; COPPER; DYSARTHRIA; DYSTONIA; EYE DISEASES; HEPATOLENTICULAR DEGENERATION; HUMANS; LIVER DISEASES; MUTATION;

EID: 77949903006     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05109.x     Document Type: Review

References (80)

1. Wilson, S. 1912. Progressive lenticular degeneration: A familial nervous disease associated with cirrhosis of the liver. Brain 34: 295-509.
2. Walshe, J.M. 1988. Wilson's disease: yesterday, today, and tomorrow. Mov. Disord. 3: 10-29.
3. Scheinberg, LH. & D. Gitlin. 1952. Deficiency of ceruloplasmin in patients with hepatolenticular degeneration (Wilson's disease). Science 116: 484-485.
4. Osborn, S.B., C.N. Roberts & J.M. Walshe. 1963. Uptake of radiocopper by the liver. A study of patients with Wilson's disease and various control groups. Clin. Sci. 24: 13-22.
5. Walshe, J.M. & G. Potter. 1977. The pattern of the whole body distribution of radioactive copper (67Cu, 64Cu) in Wilson's Disease and various control groups. Q. J. Med. 46: 445-1162
6. Beam, A.G. 1960. A genetical analysis of thirty families with Wilson's disease (hepatolenticular degeneration). Ann. Hum. Genet. 24: 33-43.
7. Bull, P.C. et al. 1993. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat. Genet. 5: 327-337. (Pubitemid 23351302)
8. Tanzi, R.E. et al. 1993. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat. Genet. 5: 344-350. (Pubitemid 23351304)
9. Yamaguchi, Y, M.E. Heiny & J.D. Gitlin. 1993. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem. Biophys. Res. Commun. 197: 271-277. (Pubitemid 23358907)
10. Cumings, J.N. 1948. The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration. Brain 71: 410-415.
11. Cumings, J.N. 1951. The effects of B.A.L. in hepatolenticular degeneration. Brain 74: 10-22.
12. Denny-Brown, D. & H. Porter. 1951. The effect of BAL (2,3-dimercaptopropanol) on hepatolenticular degeneration (Wilson's disease). N. Engl. J. Med. 245: 917-925.
13. Walshe, J.M. 1956. Penicillamine, a new oral therapy for Wilson's disease. Am. J. Med. 21: 487-495.
14. Brewer, G.J. et al. 1983. Oral zinc therapy for Wilson's disease. Ann. Intern. Med. 99: 314-319.
15. Hoogenraad, T.U., R. Koevoet & E.G. de Ruyter Korver. 1979. Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration). Eur. Neurol. 18: 205-211.
16. Walshe, J.M. & M. Yealland. 1993. Chelation treatment of neurological Wilson's disease. Q. J. Med. 86: 197-204. (Pubitemid 23120815)
17. Brewer, G.J. et al. 1994. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch. Neurol. 51: 545-554.
18. Brewer, G.J. et al. 1996. Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch. Neurol. 53: 1017-1025.
19. Brewer, G.J. et al. 2003. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch. Neurol. 60: 379-385.
20. Brewer, G.J. et al. 2006. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch. Neurol. 63: 521-527.
21. Reilly, M., L. Daly & M. Hutchinson. 1993. An epidemiological study of Wilson's disease in the Republic of Ireland. J. Neurol. Neurosurg. Psychiatry 56: 298-300. (Pubitemid 23101214)
22. Brewer, G.J. 2001. Wilson's Disease : A Clinician's Guide to Recognition, Diagnosis, and Management. Kluwer Academic. Boston.
23. Brewer, G.J. & V. Yuzbasiyan-Gurkan. 1992. Wilson disease. Medicine (Baltimore) 71: 139-164.
24. Merle, U. et al. 2007. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut 56: 115-120. (Pubitemid 46044897)
25. Ala, A. et al. 2005. Wilson disease in septuagenarian siblings: Raising the bar for diagnosis. Hepatology 41: 668-670. (Pubitemid 40289516)
26. Roberts, E.A. & M.L. Schilsky. 2003. A practice guideline on Wilson disease. Hepatology 37: 1475-1492.
27. Walshe, J.M. & M. Yealland. 1992. Wilson's disease: the problem of delayed diagnosis. J. Neurol. Neurosurg. Psychiatry 55: 692-696.
28. Giagheddu, A. et al. 1985. Epidemiologic study of hepatolenticular degeneration (Wilson's disease) in Sardinia (1902-1983). Acta Neurol Scand. 72: 43-55. (Pubitemid 16240683)
29. Machado, A. et al. 2006. Neurological manifestations in Wilson's disease: Report of 119 cases. Mov. Disord. 21: 2192-2196. (Pubitemid 46140435)
30. Oder, W et al. 1991. Neurological and neuropsychiatric spectrum of Wilson's disease: a prospective study of 45 cases. J. Neurol. 238: 281-287.
31. Starosta-Rubinstein, S. et al. 1987. Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging. Arch. Neurol. 44: 365-370. (Pubitemid 17044083)
32. Stremmel, W. et al. 1991. Wilson disease: clinical presentation, treatment, and survival. Ann. Intern. Med. 115: 720-726.
33. Taly, A.B. et al. 2007. Wilson disease: description of 282 patients evaluated over 3 decades. Medicine (Baltimore) 86: 112-121.
34. Soltanzadeh, A. et al. 2007. Wilson's disease: a great masquerader. Eur. Neurol. 57: 80-85.
35. Dening, T.R. & G.E. Berrios. 1989. Wilson's disease: clinical groups in 400 cases. Acta Neurol. Scand. 80: 527-534.
36. Denny-Brown, D. 1964. Hepatolenticular degeneration (Wilson's disease). Two different components. N. Engl. J. Med. 270: 1149-1156.
37. Okinaka, S. 1961. Studies on hepatocerebral disease. III. Hepatolenticular degeneration in Japan, with studies on copper metabolism. Neurology 11: 792-799.
38. Svetel, M. et al. 2001. Dystonia in Wilson's disease. Mov. Disord. 16: 719-723.
39. Volkmann, J. et al. 1992. Impairment of temporal organization of speech in basal ganglia diseases. Brain Lang. 43: 386-399.
40. Lorincz, M.T. 2006. Geriatric chorea. Clin. Geriatr. Med. 22: 879-897, vii.
41. Lang, C 1989. Is Wilson's disease a dementing condition? J. Clin. Exp. Neuropsychol. 11: 569-570.
42. Lang, C. et al. 1990. Neuropsychological findings in treated Wilson's disease. Acta Neurol. Scand. 81: 75-81.
43. Akil, M. 8&c G.J. Brewer. 1995. Psychiatric and behavioral abnormalities in Wilson's disease. Adv. Neurol. 65: 171-178.
44. Dening, T.R. & G.E. Berrios. 1990. Wilson's disease: a longitudinal study of psychiatric symptoms. Biol. Psychiatry 28: 255-265.
45. Dening, T.R., G.E. Berrios & J.M. Walshe. 1988. Wilson's disease and epilepsy. Brain 111(Pt 5): 1139-1155.
46. Wiebers, D.O., R.W. Hollenhorst & N.P. Goldstein. 1977. The ophthalmologic manifestations of Wilson's disease. Mayo Clin. Proc. 52: 409-416.
47. Fleming, C.R. et al. 1977. Pigmented corneal rings in non-Wilsonian liver disease. Ann. Intern. Med. 86: 285-288.
48. Prashanth, L.K. et al. 2004. Wilson's disease: diagnostic errors and clinical implications. J. Neurol Neurosurg. Psychiatry 75: 907-909.
49. Goldstein, N.P. et al. 1968. Psychiatric aspects of Wilson's disease (hepatolenticular degeneration): results of psychometric tests during long-term therapy. Am. J. Psychiatry 124: 1555-1561.
50. Dening, T.R. & G.E. Berrios. 1989. Wilson's disease. Psychiatric symptoms in 195 cases. Arch. Gen. Psychiatry 46: 1126-1134.
51. Sallie, R. et al. 1992. Failure of simple biochemical indexes to reliably differentiate fulminant Wilson's disease from other causes of fulminant liver failure. Hepatology 16: 1206-1211.
52. Ostapowicz, G. et al. 2002. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137: 947-954.
53. Ala, A. et al. 2007. Wilson's disease. Lancet 369: 397-408.
54. Ross, M.E. et al. 1985. Late-onset Wilson's disease with neurological involvement in the absence of KayserFleischer rings. Ann. Neurol 17: 411-413.
55. Shimoji, A. et al. 1987. Wilson's disease with extensive degeneration of cerebral white matter and cortex. Jpn. J. Psychiatry Neurol. 41: 709-717.
56. Ellison, D. & S. Love. 1998. Neuropathology. Mosby. Tokyo.
57. Shah, A.B. et al. 1997. Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses. Am. J. Hum. Genet. 61: 317-328.
58. Gu, Y.H. et al. 2003. Mutation spectrum and polymorphisms in ATP7B identified on direct sequencing of all exons in Chinese Han and Hui ethnic patients with Wilson's disease. Clin. Genet. 64: 479-484.
59. Kumar, S. et al. 2005. Identification, and molecular characterization of 18 novel mutations in the ATP7B gene from Indian Wilson disease patients: genotype. Clin. Genet. 67: 443-445.
60. Stapelbroek, J.M. et al. 2004. The H1069Q mutation in ATP7B is associated with late and neurologic presentation in Wilson disease: results of a meta-analysis. J. Hepatol. 41: 758-763.
61. Vrabelova, S. et al. 2005. Mutation analysis of the ATP7B gene and genotype/phenotype correlation in 227 patients with Wilson disease. Mol. Genet. Metab. 86: 277-285.
62. Magalhaes, A.C. et al. 1994. Wilson's disease: MRI with clinical correlation. Neuroradiology 36: 97-100.
63. van Wassenaer-van Hall, H.N. et al. 1996. Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology 198: 531-536.
64. Sinha, S.S. et al. 2007. Sequential MRI changes in Wilson's disease with de-coppering therapy: a study of 50 patients. Br. J. Radiol. 80: 744-749.
65. Schlaug, G. et al. 1994. Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine-therapy in Wilson's disease. J. Neurol. 241: 577-584.
66. Brewer, G.J. et al. 1987. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch. Neurol. 44: 490-493.
67. Prashanth, L.K. et al. 2005. Prognostic factors in patients presenting with severe neurological forms of Wilson's disease. QJM 98: 557-563.
68. Czlonkowska, A., J. Gajda & M. Rodo. 1996. Effects of long-term treatment in Wilson's disease with Dpenicillamine and zinc sulphate. J. Neurol 243: 269-273. (Pubitemid 26071990)
69. Hoogenraad, T.U. 2006. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice. Brain Dev. 28: 141-146.
70. Brewer, G.J., V. Yuzbasiyan-Gurkan & D.Y.Lee. 1990. Use of zinc-copper metabolic interactions in the treatment of Wilson's disease. J. Am. Coll. Nutr. 9: 487-491.
71. Marcellini, M. et al. 2005. Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study. J. Lab. Clin. Med. 145: 139-143. (Pubitemid 40432363)
72. Hockly, E. et al. 2002. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 51: 235-242. (Pubitemid 34111446)
73. Hoogenraad, T.U. 1998. Zinc treatment of Wilson's disease. J. Lab. Clin. Med. 132: 240-241.
74. Hoogenraad, T.U. & J. Van Hattum. 1988. Zinc therapy as the initial treatment for Wilson's disease. Arch. Neurol. 45: 373-374.
75. Hoogenraad, T.U., J. Van Hattum & C. J. Van Den Hamer. 1987. Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients. J. Neurol Sci. 77: 137-146.
76. Anderson, L.A., S.L. Hakojarvi. & S.K. Boudreaux. 1998. Zinc acetate treatment in. Wilson's disease. Ann. Pharmacother. 32: 78-87. (Pubitemid 28087239)
77. Eghtesad, B. et al. 1999. Liver transplantation for Wilson's disease: a single-center experience. Liver Transpl. Surg. 5: 467-474. (Pubitemid 29517860)
78. Schumacher, G. et al. 1997. Liver transplantation: treatment of choice for hepatic and neurological manifestation of Wilson's disease. Clin. Transplant. 11: 217-224. (Pubitemid 27230801)
79. Rodriguez, R.T. et al. 2007. Manipulation of OCT4 levels in human embryonic stem cells results in induction of differential cell types. Exp. Biol. Med. (Maywood) 232: 1368-1380.
80. Nazer, H. et al. 1986. Wilson's disease: clinical presentation and use of prognostic index. Gut 27: 1377-1381. (Pubitemid 17175689)